3T Biosciences is an immunotherapy company that develops next-generation therapies for cancer and immune-mediated diseases.
3T Biosciences has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in August 2022.
3T Biosciences's investors include Menlo Ventures, Lightspeed Venture Partners, CRV, Westlake Village BioPartners, Starlight Ventures.
3T Biosciences is headquartered in Menlo Park, United States.
3T Biosciences is an immunotherapy company that develops next-generation therapies for cancer and immune-mediated diseases.
3T Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"3T Biosciences — Funding & Investors." VCBacked, August 25, 2022, https://www.vcbacked.co/company/3t-biosciences. Accessed September 22, 2026.
VCBacked. (2022). 3T Biosciences — Funding & Investors. Retrieved September 22, 2026, from https://www.vcbacked.co/company/3t-biosciences
{{cite web |title=3T Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/3t-biosciences |website=VCBacked |access-date=September 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated